ArticleCancers2022
Volatilome Analysis in Prostate Cancer by Electronic Nose: A Pilot Monocentric Study.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Exploring Components, Sensors, and Techniques for Cancer Detection via eNose Technology: A Systematic Review.Sensors (Basel, Switzerland) · 2024Pooled it
- Olfactory Science and Technology in Prostate Cancer Diagnosis: From Invertebrate Models to Artificial Intelligence.Life (Basel, Switzerland) · 2026Review
- Non-Invasive Detection of Tumors by Volatile Organic Compounds in Urine.Biomedicines · 2025Review
- Article
- Analysis of urinary volatile organic compounds for prostate cancer diagnosis: A systematic review.BJUI compass · 2024Review
- Prostate cancer risk stratification via eNose urine odor analysis: a preliminary report.Frontiers in oncology · 2024Article
- Non-Invasive Blood Pressure Tracking of Spontaneous Hypertension Rats Using an Electronic Nose.Sensors (Basel, Switzerland) · 2023Article
- Point-of-Care Disease Screening in Primary Care Using Saliva: A Biospectroscopy Approach for Lung Cancer and Prostate Cancer.Journal of personalized medicine · 2023Article
- Differences in the Volatilomic Urinary Biosignature of Prostate Cancer Patients as a Feasibility Study for the Detection of Potential Biomarkers.Current oncology (Toronto, Ont.) · 2023Article
- Article
- The function of Prostate Health Index in detecting clinically significant prostate cancer in the PI-RADS 3 population: a multicenter prospective study.World journal of urology · 2023Article
- Volatilomics: An Emerging and Promising Avenue for the Detection of Potential Prostate Cancer Biomarkers.Cancers · 2022Review
- Article
- Comparison of Morphological and Functional MRI Assessments of Periprostatic Fat for Predicting Prostate Cancer Aggressiveness.International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Urine analysis via an electronic nose provides volatile organic compounds easily usable in the diagnosis of urological diseases. Although challenging and highly expensive for health systems worldwide, no useful markers are available in clinical practice that aim to anticipate prostate cancer (PCa) diagnosis in the early stages in the context of wide population screening. Some previous works suggested that dogs trained to smell urine could recognize several types of cancers with various success rates. We hypothesized that urinary volatilome profiling may distinguish PCa patients from healthy controls. In this study, 272 individuals, 133 patients, and 139 healthy controls participated. Urine samples were collected, stabilized at 37 °C, and analyzed using a commercially available electronic nose (Cyranose C320). Statistical analysis of the sensor responses was performed off-line using principal component (PCA) analyses, discriminant analysis (CDA), and ROC curves. Principal components best discriminating groups were identified with univariable ANOVA analysis. groups were identified with univariable ANOVA analysis. Here, 110/133 and 123/139 cases were correctly identified in the PCa and healthy control cohorts, respectively (sensitivity 82.7%, specificity 88.5%; positive predictive value 87.3%, negative predictive value 84.2%). The Cross Validated Accuracy (CVA 85.3%, p < 0.001) was calculated. Using ROC analysis, the area under the curve was 0.9. Urine volatilome profiling via an electronic nose seems a promising non-invasive diagnostic tool.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.